Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.09) by 12.84 percent. This is a 126.19 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $875.000 thousand which missed the analyst consensus estimate of $1.393 million by 37.20 percent. This is a 95.74 percent decrease over sales of $20.558 million the same period last year.